Vontobel Holding
NBIX icon

Vontobel Holding’s Neurocrine Biosciences NBIX Stock Holding History

Vontobel Holding’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Buy
2,857
+29
+1% +$4.3K ﹤0.01% 1063
2026
Q1 		$373K Buy
2,828
+106
+4% +$14.1K ﹤0.01% 938
2025
Q4 		$386K Sell
2,722
-13
-0.5% -$1.88K ﹤0.01% 1081
2025
Q3 		$384K Sell
2,735
-1,376
-33% -$186K ﹤0.01% 1032
2025
Q2 		$517K Sell
4,111
-5,832
-59% -$669K ﹤0.01% 887
2025
Q1 		$1.1M Buy
9,943
+1,501
+18% +$190K ﹤0.01% 566
2024
Q4 		$1.15M Sell
8,442
-6,148
-42% -$760K ﹤0.01% 558
2024
Q3 		$1.68M Buy
14,590
+1,639
+13% +$225K 0.01% 486
2024
Q2 		$1.78M Buy
12,951
+4,801
+59% +$658K 0.01% 448
2024
Q1 		$1.12M Buy
8,150
+2,061
+34% +$281K 0.01% 552
2023
Q4 		$802K Sell
6,089
-2,369
-28% -$273K 0.01% 659
2023
Q3 		$952K Sell
8,458
-1,250
-13% -$132K 0.01% 596
2023
Q2 		$915K Sell
9,708
-595
-6% -$58.1K 0.01% 620
2023
Q1 		$1.04M Buy
10,303
+7,082
+220% +$737K 0.01% 576
2022
Q4 		$382K Sell
3,221
-2,644
-45% -$310K ﹤0.01% 827
2022
Q3 		$603K Buy
5,865
+959
+20% +$97.3K 0.01% 660
2022
Q2 		$482K Sell
4,906
-35,189
-88% -$3.25M 0.01% 733
2022
Q1 		$3.71M Buy
40,095
+18,222
+83% +$1.54M 0.03% 320
2021
Q4 		$1.85M Buy
21,873
+3,890
+22% +$358K 0.02% 460
2021
Q3 		$1.72M Sell
17,983
-1,386
-7% -$131K 0.02% 476
2021
Q2 		$1.88M Buy
19,369
+3,374
+21% +$323K 0.02% 452
2021
Q1 		$1.56M Sell
15,995
-2,858
-15% -$300K 0.01% 452
2020
Q4 		$2.22M Buy
+18,853
New +$1.82M 0.01% 386

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vontobel Holding's NBIX Position: Q2 2026 in Review

Vontobel Holding increased its Neurocrine Biosciences (NBIX) stake by 1% in Q2 2026, buying an estimated $4.3K and bringing the position to 2,857 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

Vontobel Holding first reported a position in NBIX in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.71M in Q1 2022. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Vontobel Holding held 2,857 shares of Neurocrine Biosciences worth $482K as of Q2 2026.
  • Vontobel Holding bought 29 Neurocrine Biosciences shares in Q2 2026, an estimated $4.3K.
  • Neurocrine Biosciences made up ﹤0.01% of Vontobel Holding's portfolio in Q2 2026, its #1063 holding.
  • Vontobel Holding first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 23 quarters since.
  • Vontobel Holding's Neurocrine Biosciences position peaked at $3.71M in Q1 2022.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.